Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00866697 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 3 study of Ovarian Cancer, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
940
Enrollment target
20
Study locations

NCT00866697: Completed Phase 3 study of Ovarian Cancer, sponsored by Novartis Pharmaceuticals.

NCT00866697 is a Phase 3 study of Ovarian Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 940 participants, above the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00866697, a Phase 3 study of Ovarian Cancer, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
940 participants
Enrollment target
20
Study locations

Study Summary

This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.

Primary Outcome

PFS is the interval between the date of randomization and the date of progression, defined by Response Evaluation Criteria in Solid Tumors (RECIST), or death due to any cause. Per RECIST, for target lesions (TLs), disease progression (PD) is defined as \>=20% increase in the sum of the longest diameters (LD) of TLs, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of \>=1 new lesions. For non-target lesions (NTLs), PD is defined as the appearance

Conditions Studied

Ovarian Cancer

Interventions

  • DRUG Placebo
  • DRUG Pazopanib

Study Locations (20)

California

  • Novartis Investigative Site - Anaheim
  • Novartis Investigative Site - Baldwin Park
  • Novartis Investigative Site - Bellflower
  • Novartis Investigative Site - Duarte
  • Novartis Investigative Site - Fontana
  • Novartis Investigative Site - Hayward
  • Novartis Investigative Site - Irvine
  • Novartis Investigative Site - Long Beach
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Oakland
  • Novartis Investigative Site - Ontario
  • Novartis Investigative Site - Orange
  • Novartis Investigative Site - Panorama City
  • Novartis Investigative Site - Riverside
  • Novartis Investigative Site - Roseville
  • Novartis Investigative Site - Sacramento
  • Novartis Investigative Site - Sacramento
  • Novartis Investigative Site - San Diego

Trial Details

FieldValue
Enrollment Target 940 participants
Start Date 2009-05-26
Est. Completion 2017-08-24
Phase Phase 3
Novartis Pharmaceuticals

1,375 total trials

What the finished NCT00866697 record still lists

NCT00866697 is an interventional study that assigns participants to a tested intervention. The registered 940 participants enrollment target is mid-sized for trials with a published cap, above the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (29% higher).

The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00866697 names 20 study sites across 1 states, led by California.

Frequently Asked Questions

What is clinical trial NCT00866697 about?

NCT00866697 is a clinical study titled "Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.

What is the current status of trial NCT00866697?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 940 participants. The study started on 2009-05-26. Estimated completion is 2017-08-24.

What conditions does trial NCT00866697 study?

This clinical trial studies the following conditions: Ovarian Cancer.

What interventions are being tested in trial NCT00866697?

The interventions under investigation include: Placebo (DRUG), Pazopanib (DRUG).

Who is sponsoring clinical trial NCT00866697?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00866697 being conducted?

This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00866697's enrollment target sits among peer trials

940 27th of 322 higher than 296 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03075696 · 940 participants · Phase 1

    A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

  • NCT06855277 · 940 participants · Phase 3

    Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  • NCT06808334 · 942 participants

    CLAiR Pivotal Study

  • NCT07190209 · 942 participants · Phase 3

    Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00866697, the US trial registry maintained by the National Library of Medicine. NCT00866697 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.